ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

Komen Foundation Offer Fellowships

February 9, 1996

Genomic Test More Accurate In Predicting Metastasis Than PSA, Tumor Stage & Grade

February 22, 2013

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

Varmus, Branscomb Win Public Service Award From NSF; NCI Clarifies Plans For Large R01s

June 1, 2001

CCRU-CCSP Report At Closed Session “Declassified” Discusses Review

December 3, 1982

Dear FDA: Provenge Provokes Letters From Opponents, Advocates, Investors.

April 27, 2007